Ayahuasca

Ayahuasca’s origins trace back millennia among Amazonian tribes, but its compounds entered scientific awareness in the mid-20th century. In 1956 Hungarian chemist Stephen Szára was the first to synthesize DMT and self-administer it, noting its vivid effects. Traditional use continued largely unreported in Western science until ethnobotanists (e.g. R. Evans Schultes in the 1940s) brought attention to the brew. DMT was later placed in UN Schedule I (1971), which stifled research. Meanwhile, the Santo Daime and União do Vegetal churches incorporated ayahuasca into syncretic rituals, and Brazil legally exempted ayahuasca for religious use in 1987. The late 20th century saw sporadic studies: Grob et al. (1996) tested the safety of harmine in humans; Callaway (1999) elucidated MAO interactions; Riba and colleagues (early 2000s) performed controlled pharmacology and neuroimaging studies. The modern research renaissance really took hold in the 2010s. Key publications include open-label trials of ayahuasca in depression (Osório et al. 2015; Sanches et al. 2016) and the first placebo-controlled RCT (Palhano-Fontes et al. 2019). These followed rising general interest in psychedelics, new funding (e.g. Heffter Foundation support), and advances in brain-imaging methods. In 2026, Erritzoe et al. reported the first controlled trial of DMT infusion for depression, cementing ayahuasca’s relevance. Institutional milestones include the 2006 U.S. Supreme Court ruling (UDV v. Gonzales) allowing religious ayahuasca use and major labs taking up ayahuasca studies (e.g. Maastricht Univ., Imperial College London, Federal U. of Rio Grande do Norte). In short, ayahuasca research evolved from anthropological notes to pharmacological characterization, a hiatus under prohibition, then a sophisticated revival in clinical neuroscience over the past decade.

Ayahuasca’s effects arise from a complex interplay of compounds. The primary psychoactive, DMT, is a potent agonist at serotonin 5-HT2A receptors (with substantial partial activity at 5-HT2C, and some binding at 5-HT1A and the σ1 receptor). The co-administered β-carbolines (harmine, harmaline, THH) from B. caapi are potent reversible MAO-A inhibitors. This MAO-A blockade prevents first-pass catabolism of DMT, making oral dosing active. By comparison to IV or smoked DMT (onset seconds, ~15–30min duration), ayahuasca’s effects come on more slowly and last ~3–4h. Pharmacokinetic studies show DMT’s plasma half-life is only ~0.6h when combined with harmine, though harmine’s own half-life (~1.4h) prolongs the overall experience. In healthy volunteers, C_max of DMT is reached ~75min post-ingestion. Dose-response has been characterized mostly in small studies, but subjective intensity rises with DMT/harmine dose; one first-in-human trial found that higher intranasal DMT+oral harmine doses produced proportionally stronger psychedelic ratings without new safety signals. Neurobiologically, ayahuasca suppresses default-mode network connectivity and alters activity in limbic and visual areas. Post-dose, it elevates peripheral biomarkers of plasticity: for example, blood BDNF levels rise significantly by 24–48h. Animal models also show DMT stimulates hippocampal neural progenitors and angiogenesis, suggesting a broad neurotrophic mechanism.

The safety profile of ayahuasca in controlled settings is generally favourable. In pooled analyses of clinical trials (over 100 administrations), the most common adverse events were expected serotonergic effects: gastrointestinal upset (nausea, vomiting, diarrhea), transient headaches, and mild-to-moderate increases in heart rate and blood pressure. Some participants experience acute anxiety, confusion or dysphoria during the peak, but there are no reports of lasting psychosis or cognitive deficits. Critically, no serious organ toxicities or fatalities have been documented in the literature. In the pivotal 2019 TRD study, 100% of patients vomited, but none suffered lasting harm, and all reported feeling physically safe during the session. No tolerance or dependence has been observed even with repeated ceremonial use. Contraindications include personal or family history of psychosis or bipolar disorder, uncontrolled cardiovascular disease, and pregnancy. Drug–drug interactions are important: co-use with SSRIs, SNRIs or MAO inhibitors can precipitate serotonin syndrome or hypertensive crises. Lithium is also avoided (risks of seizures seen with other psychedelics). Because ayahuasca inherently contains MAOIs, standard dietary restrictions (low tyramine) are often recommended. There is no approved REMS or formal guidance, but best practice involves thorough screening, medical monitoring during ceremonies, and integration support. In general, a comfortable, supportive set-and-setting is emphasised to mitigate the mild anxiety or “challenging” experiences that may occur.

Major trials completed or underway include: the Palhano-Fontes et al. Phase II RCT (U. Federal RN, Brazil; NCT02914769) in treatment-resistant depression (29 patients), which showed large antidepressant effects. Erritzoe et al. (Imperial College/Helus Pharma) conducted a Phase IIa RCT of IV DMT in moderate-to-severe MDD (n≈34, NCT03715127), finding rapid symptom reduction. A first-in-human PK trial (NCT04716335, U. Zurich) tested intranasal DMT plus oral harmine in 10 volunteers; it found that the novel delivery greatly reduced nausea and yielded consistent blood levels. Brazilian investigators (USP, UFRN) have also run small open-label studies (Sanches et al., Osório et al.) and a scheduled Phase II comparing ayahuasca vs. esketamine in depression (NCT07212946), and a PTSD trial (NCT07317206). On the observational side, projects like the Ayahuasca Treatment Outcome Project (Takiwasi, Peru) have published one-year results for addiction. Leading academic groups include the Federal U. of Rio Grande do Norte (Natal, Brazil), Univ. of São Paulo, Maastricht University (Donders Institute, Netherlands), U. of Zurich, Imperial College London, and the Heffter Research Institute (USA). No regulatory Breakthrough or Fast-Track designations are currently granted for ayahuasca itself; however, DMT-assisted programs might seek such pathways if late-stage data accrue.

The most advanced indication is major depressive disorder (especially TRD). Ayahuasca’s rapid-onset mood effects (evident by 24–72h post-dose) make it a candidate for TRD or severe acute depression. Ongoing trials will clarify optimal dosing/frequency and whether effects sustain beyond one or two doses. Other indications in development: PTSD is being tested (e.g. Brazilian Phase II NCT07317206) due to anecdotal reports of trauma processing. Substance use disorders (alcohol, opioids, stimulants, nicotine) show promise from observational data; formal trials are planned in some addiction clinics. Preliminary cases suggest potential in eating disorders: a small case series reported fewer binge-eating days after ayahuasca. Controlled research is very limited for these emerging uses, but the pilot data encourage further study. Neurologic/degenerative applications are speculative: DMT’s neurogenic effects in animals hint at Alzheimer’s or TBI research interest, but no human studies exist. In all cases, patient selection will likely exclude psychotic or unstable personalities. Importantly, clinicians note that set-and-setting (psychological preparation and integration) appears crucial to outcomes, and this non-pharmacologic component will be an important focus of future protocols.

Under international convention, DMT is Schedule I and tightly controlled. Consequently, most countries outlaw ayahuasca. In the US, ayahuasca is illegal (Schedule I) except for granted religious use. The Supreme Court’s 2006 decision (Gonzales v. O Centro) allowed the União do Vegetal church to use ayahuasca sacramentally, and a 2009 injunction protected the Santo Daime church likewise. In the UK, DMT is a Class A drug, making ayahuasca brew illegal. The EU has no unified stance: some countries (e.g. Spain) tolerate ayahuasca ceremonies via religious exemption, others (Germany, France) enforce bans. Brazil’s government explicitly permits ayahuasca in religious contexts since 1987. Australia’s TGA classifies DMT as Schedule 9 (prohibited), and New Zealand likewise prohibits it. In Canada, DMT is Schedule III, but the government granted a Section 56 exemption to a Santo Daime church in 2017. No health authority has approved ayahuasca or DMT as a therapy; any medical use today is off-label or anecdotal. A plausible regulatory path would require standardizing a formulation (e.g. pharmahuasca) and conducting Phase III trials for a specific indication, followed by an NDA/MAA. However, no company has yet filed such an application, so timelines remain speculative and hinge on upcoming trial outcomes.

No major pharmaceutical company has an approved ayahuasca product, but some biotech startups target its active chemistry. Helus Pharma (formerly Cybin) is the furthest along with an intravenous DMT formulation (SPL026), which completed Phase IIa with positive mood effects. Other small firms are exploring routes to market: formulations combining synthetic DMT and harmine (“pharmahuasca”) or novel delivery systems (e.g. intranasal, sublingual) are in development. Patent strategies focus on delivery technology or DMT analogues, since natural ayahuasca cannot be patented. Commercial interest is tempered by the complexity of standardizing a botanical mix and by regulatory hurdles. Nonetheless, significant venture funding has entered the broader psychedelic field (with some allocated to DMT research), and positive Phase II data have attracted investor attention. If late-stage trials succeed, the first branded DMT-based therapy could reach the market in the early 2030s, though this is contingent on regulatory rescheduling in key markets. Presently, activity is greatest in the US, Canada, EU and Israel (Helus), with potential emergence of Latin American clinics leveraging legal status. No mergers or acquisitions specifically for ayahuasca drug programmes have been announced to date.

Ayahuasca is a classic serotonergic psychedelic, so its nearest comparators are other 5-HT2A agonists. Compared to psilocybin (also a tryptamine), ayahuasca’s effects are similarly visual but often more intense emotionally (including purging) and are usually shorter (4–6h vs ~6h for psilocybin). LSD (an ergoline) has a much longer duration (8–12h) and is active at microgram doses; it also produces fewer bodily effects (e.g. LSD generally causes little nausea). Ayahuasca’s active DMT is identical to N,N-DMT when smoked or IV, but the brew (with MAOIs) makes the experience longer and orally dosed. In comparison to dissociatives like ketamine/esketamine (NMDA antagonists), ayahuasca has a different mechanism (serotonergic) and typically induces hallucinations, whereas ketamine induces dissociation without classic visual trips. Ayahuasca’s onset is slower than IV ketamine (minutes) but faster than most SSRIs or oral antidepressants; its antidepressant effects may be as rapid as ketamine’s, yet appear to sustain longer (ketamine often requires repeated doses, whereas a single ayahuasca session can have enduring effects). Safety/tolerability wise, all these psychedelics have low physiological toxicity: none are associated with serious organ damage or lethal overdose at clinical doses. Ayahuasca’s added risk (temporary hypertension during MAOI phase, plus dehydration risk from vomiting) is manageable under supervision. From a development standpoint, psilocybin has more advanced commercial backing (Phase III) and a synthetic GMP supply, while ayahuasca’s botanical variability complicates scale-up. Nonetheless, ayahuasca’s unique profile (combined DMT+MAOI, rapid mood lifting without tolerance) may carve a niche in depression or addiction therapy alongside its analogues.